Login to Your Account



Clinic Roundup


Thursday, February 3, 2011
United Therapeutics Corp., of Silver Spring, Md., said it completed enrollment in its FREEDOM-M registration trial testing a sustained-release, oral formulation of treprostinil diethanolamine in pulmonary arterial hypertension (PAH) patients not receiving any other approved PAH therapy. The study enrolled 349 patients, above the target enrollment of 315.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription